Prader-Willi Syndrome (PWS) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Prader-Willi Syndrome (PWS) – Drugs In Development, 2024 report and make more profitable business decisions.
Prader-Willi syndrome (PWS) is a rare congenital genetic disorder that results in a number of physical, mental, and behavioral problems. PWS is due to the lack of several genes on one of an individual’s two chromosome 15s. In the majority of cases, there is a deletion. In the remaining cases, the entire chromosome from the father is missing and there are instead two chromosome 15’s from the mother (uniparental disomy). Symptoms include poor muscle tone, low levels of sex hormones, and a constant feeling of hunger.
The Prader-Willi Syndrome (PWS) drugs in development market research report provide comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Prader-Willi Syndrome (PWS) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Prader-Willi Syndrome (PWS) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 33 molecules, with 30 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Prader-Willi Syndrome (PWS) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Prader-Willi Syndrome (PWS) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Prader-Willi Syndrome (PWS) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
9 Meters Biopharma IncAardvark Therapeutics Inc
Acadia Pharmaceuticals Inc
Agentix Corp
Albert Einstein College of Medicine
Altamira Therapeutics Ltd
Astrogen Ltd
Beryl Therapeutics Inc
Biomind Labs Inc
Carmot Therapeutics Inc
Cerevance Inc
ConSynance Therapeutics Inc
Duke University
Efil Bioscience Inc
EPM Group Inc
Gedeon Richter Plc
GLWL Research Inc
Harmony Biosciences Holdings Inc
Helsinn Healthcare SA
Inversago Pharma Inc
Lipidio Pharmaceuticals Inc
Lumos Pharma Inc
Neuracle Science Co Ltd
Neuren Pharmaceuticals Ltd
Notitia Biotechnologies Co
OptiNose Inc
OT4B
Palo BioFarma SL
Soleno Therapeutics Inc
Taysha Gene Therapies Inc
The Walter and Eliza Hall Institute of Medical Research
Tonix Pharmaceuticals Holding Corp
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Prader-Willi Syndrome (PWS) reports